In a blinded phase 3 study, doravirine and islatravir was compared to antiretroviral therapy, BIC/FTC/TAF (Biktarvy), and it was shown that there was no between-group differences in mean change in CD4 T-cell or total lymphocyte count at week 48.
Luisa Stamm, MD, PhD
Advertisement
Stamm is associate vice president, Infectious Disease Clinical Research, section head, HIV, Merck.
Articles by Luisa Stamm, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Nearly 1 in 5 Urinary Tract Infections in Southern California Linked to Contaminated Meat
2
Moderna Discontinues Development of Vaccine for Congenital CMV After Not Meeting Primary Efficacy Endpoint
3
Dynavax Presents Data for Shingles Vaccine, Launches Head-to-Head Study Against Shingrix
4
Risk Stratification, Testing, and Treatment in Recurrent Clostridioides difficile
5
